# US 2005/0233386 A1 · Human hematopoietic growth regulatory gene and uses

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2005/0233386 A1
- Document ID: US20050233386A1
- Status: Published application
- Kind: A1
- Application number: 11/141,072
- Filed: 2005-05-31
- Published: 2005-10-20
- Earliest claimed: 2002-01-10
- Assignees: The Board of Trustees of the University of Illinois
- Inventors: Arun Sharma; Ronald Hoffman
- Web page: https://patentgrep.com/patent/US20050233386A1

## CPC

- C12N 5/0647: {Haematopoietic stem cells; Uncommitted or multipotent progenitors}
- C07K 14/4702: {Regulators; Modulating activity}
- C12N 2501/125: Stem cell factor [SCF], c-kit ligand [KL]
- C12N 2501/23: Interleukins [IL]
- C12N 2501/40: Regulators of development
- C12N 2510/00: Genetically modified cells
- C12N: MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA (microbiological testing media C12Q1/00)
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)

## Abstract

The present invention relates to novel human hiwi protein and genes that encode such proteins. The invention is directed toward the isolation and characterization of human hiwi proteins. The invention specifically provides isolated complementary DNA copies of mRNA corresponding to a human hiwi gene. Also provided are recombinant expression constructs capable of expressing the human hiwi gene of the invention in cultures of transformed prokaryotic and eukaryotic cells, as well as such cultures of transformed cells that synthesize the human hiwi proteins encoded therein. The invention also provides methods for isolating human hematopoietic stem cells.

## Claims

### Claim 1

A homogeneous composition of a human hiwi gene product having a molecular weight of about 90 kilodaltons and an amino acid sequence identified by (SEQ ID No.: 2).

### Claim 2

A cell membrane preparation comprising a human hiwi gene product or derivative thereof having a molecular weight of about 90 kilodaltons and an amino acid sequence identified by SEQ ID No.: 2.

### Claim 3

A cytosolic preparation comprising a human hiwi gene product or derivative thereof having a molecular weight of about 90 kilodaltons and an amino acid sequence identified by SEQ ID No.: 2.

### Claim 4

A cell nuclear preparation comprising a human hiwi gene product or derivative thereof having a molecular weight of about 90 kilodaltons and an amino acid sequence identified by SEQ ID No.: 2.

### Claim 5

A method for identifying a compound that induces or increases hiwi gene expression in mammalian cells, the method comprising the steps of:
a) culturing a mammalian cell under conditions wherein the cell does not express the hiwi gene or expresses an amount of the hiwi gene product insufficient to repress cell proliferation;
b) contacting the cell with a test compound for a time period;
c) assaying the cells at intervals during the time period for hiwi gene expression and cell proliferation or apoptosis; and
d) identifying compounds that induce hiwi gene expression, and concomitantly decrease cell proliferation or increase the percentage of cells undergoing apoptosis or both.

### Claim 6 (depends on 5)

The method of claim 5, wherein the cells are human cells.

### Claim 7 (depends on 6)

The method of claim 6, wherein the cells are leukemia cells or hematopoietic stem cells.

### Claim 8 (depends on 6)

The method of claim 6, wherein the cells are human leukemia cells or human hematopoietic stem cells.

### Claim 9 (depends on 5)

A method for increasing retention of primitive CD34+ hematopoietic stem cells in an in vitro bone marrow or peripheral blood culture, the method comprising the step of culturing the bone marrow or peripheral blood culture in the presence of a compound identified by the method of claim 5.

### Claim 10 (depends on 5)

A method for increasing retention of primitive CD34+ hematopoietic stem cells in an in vitro bone marrow or peripheral blood culture, the method comprising the step of introducing into the primitive CD34+ hematopoietic stem cells a recombinant expression construct according to claim 5.

### Claim 11 (depends on 10)

A method according to claim 10, wherein the recombinant expression construct comprises a retroviral or lentiviral vector.

### Claim 12 (depends on 10)

A method according to claim 10, wherein expression of the hiwi gene product by the recombinant expression construct is inducible expression.
